All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
The MPN Hub was pleased to speak with Jean-Jacques Kiladjian, Professor of Clinical Pharmacology at Université Paris Cité, Paris, France. We asked, What is the impact of momelotinib on transfusion dependence and quality of life (QoL) in myelofibrosis (MF)?
Momelotinib: Impact on transfusion dependence and QoL in MF
Kiladjian highlights the reduction of transfusion dependence and symptoms for patients with MF and anemia treated with momelotinib. He reviews key data from the phase III SIMPLIFY-1 (NCT01969838), SIMPLIFY-2 (NCT02101268), and MOMENTUM (NCT04173494) studies, and the implications of these findings for treatment algorithms in patients with MF.
Agree
100%
Disagree
0%
This educational resource is independently supported by GSK. All content is developed by SES in collaboration with an expert steering committee; funders are allowed no influence on the content of this resource.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox